Cite
Treatment extension may benefit female genotype 1 chronic hepatitis C patients with complete early virological response to peginterferon-alpha-2b and ribavirin combination therapy.
MLA
Nishimura, Takeshi, et al. “Treatment Extension May Benefit Female Genotype 1 Chronic Hepatitis C Patients with Complete Early Virological Response to Peginterferon-Alpha-2b and Ribavirin Combination Therapy.” Hepatology Research, vol. 42, no. 10, Oct. 2012, pp. 966–73. EBSCOhost, https://doi.org/10.1111/j.1872-034X.2012.01016.x.
APA
Nishimura, T., Yamaguchi, K., Hashimoto, H., Niimi, T., Yokomizo, C., Fujii, H., Minami, M., Sakamoto, M., Ohnish, N., Nagao, Y., Okita, M., Umemura, A., Shima, T., Okanoue, T., & Itoh, Y. (2012). Treatment extension may benefit female genotype 1 chronic hepatitis C patients with complete early virological response to peginterferon-alpha-2b and ribavirin combination therapy. Hepatology Research, 42(10), 966–973. https://doi.org/10.1111/j.1872-034X.2012.01016.x
Chicago
Nishimura, Takeshi, Kanji Yamaguchi, Hiroaki Hashimoto, Toshihisa Niimi, Chihiro Yokomizo, Hideki Fujii, Masahito Minami, et al. 2012. “Treatment Extension May Benefit Female Genotype 1 Chronic Hepatitis C Patients with Complete Early Virological Response to Peginterferon-Alpha-2b and Ribavirin Combination Therapy.” Hepatology Research 42 (10): 966–73. doi:10.1111/j.1872-034X.2012.01016.x.